# Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Participants

> **NCT02302066** · PHASE2 · COMPLETED · sponsor: **Takeda** · enrollment: 1800 (actual)

## Conditions studied

- Dengue Fever

## Interventions

- **BIOLOGICAL:** Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
- **BIOLOGICAL:** TDV Placebo

## Key facts

- **NCT ID:** NCT02302066
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-05
- **Primary completion:** 2019-02-18
- **Final completion:** 2019-02-18
- **Target enrollment:** 1800 (ACTUAL)
- **Last updated:** 2020-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02302066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02302066, "Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Participants". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02302066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*